

Amendment Statement of Principles

concerning

SARCOIDOSIS  
(Reasonable Hypothesis)

(No. 13 of 2019)

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(2) and (8) of the *Veterans' Entitlements Act 1986*.

Dated 21 December 2018

|  |
| --- |
| The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of: |
| Professor Nicholas Saunders AO  Chairperson |

Contents

1 Name 3

2 Commencement 3

3 Authority 3

4 Amendment 3

1. Name

This is the Amendment Statement of Principles concerning *sarcoidosis* *(Reasonable Hypothesis)* (No. 13 of 2019).

1. Commencement

This instrument commences on 28 January 2019.

1. Authority

This instrument is made under subsections 196B(2) and (8) of the *Veterans' Entitlements Act 1986*.

1. Amendment

The Statement of Principles concerning *sarcoidosis* *(Reasonable Hypothesis)* (No. 59 of 2016) (Federal Register of Legislation No. F2016L01144) is amended in the following manner:

|  |  |
| --- | --- |
| **Section** | **Amendment** |
| 9(1) | *Replace the existing factor in subsection 9(1) with the following*:  being treated with a drug from a class of drugs from the specified list of drugs within the five years before the clinical onset of sarcoidosis;  Note: ***specified list of drugs*** is defined in the Schedule 1 - Dictionary. |
| 9(1a) | *Insert the following factor in subsection 9(1a):*  having immunotherapy for cancer or targeted therapy for cancer within the five years before the clinical onset of sarcoidosis;  Note: ***immunotherapy for cancer*** and ***targeted therapy for cancer*** are defined in the Schedule 1 - Dictionary. |
| 9(3a) | *Insert the following factor in subsection 9(3a):*  having a malignant neoplasm in the ten years before the clinical onset of sarcoidosis; |
| 9(6) | *Replace the existing factor in subsection 9(6) with the following*:  being treated with a drug from a class of drugs from the specified list of drugs within the five years before the clinical worsening of sarcoidosis;  Note: ***specified list of drugs*** is defined in the Schedule 1 - Dictionary. |
| 9(6a) | *Insert the following factor in subsection 9(6a):*  having immunotherapy for cancer or targeted therapy for cancer within the five years before the clinical worsening of sarcoidosis;  Note: ***immunotherapy for cancer*** and ***targeted therapy for cancer*** are defined in the Schedule 1 - Dictionary. |
| 9(8a) | *Insert the following factor in subsection 9(8a):*  having a malignant neoplasm in the ten years before the clinical worsening of sarcoidosis; |
| Schedule 1 – Dictionary | *Insert the following definition of "immunotherapy for cancer" in alphabetical order:*  ***immunotherapy for cancer*** means the use of drugs to stimulate a person's own immune system to recognise and destroy cancer cells more effectively. |
| Schedule 1 – Dictionary | *Insert the following definition of "specified list of drugs" in alphabetical order:*  ***specified list of drugs*** means:   1. BRAF/MEK inhibitors, including, but not limited to, vemurafenib, dabrafenib and trametinib; 2. immune checkpoint inhibitors, including, but not limited to, ipilimumab, pembrolizumab and nivolumab; 3. interferons; or 4. vaccines used to treat cancer. |
| Schedule 1 – Dictionary | *Insert the following definition of "targeted therapy for cancer" in alphabetical order:*  ***targeted therapy for cancer*** means the use of drugs that block the growth and spread of cancer by interfering with specific molecules that are involved in the growth, progression or spread of cancer. |